Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery

Hormone and Metabolic Research

Volumn 43, Issue 6, 2011, Pages 433-439

  Chen, H S ^a,b   Wu, T E ^b,c   Jap, T S ^a,b   Hsiao, L C ^a   Lin, H D ^a,b   Lee, S H ^a   Lin, S H ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

acromegaly; diabetes; octreotide; oral glucose tolerance test

Indexed keywords

GLUCOSE; GROWTH HORMONE; INSULIN; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RELEASE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLYCEMIC INDEX; GROWTH HORMONE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INJECTION; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; MALE; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL TECHNIQUE; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT OUTCOME;

ACROMEGALY; ADULT; AGED; BLOOD GLUCOSE; FEMALE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INSULIN; MALE; MIDDLE AGED; OCTREOTIDE; SPHENOID BONE; YOUNG ADULT;

EID: 79957851618     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1275703     Document Type: Article

References (29)

1. Melmed S, Jackson I, Kleinberg D, Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998 83 2646-2652 (Pubitemid 28493755)
2. Harris AG. Acromegaly: epidemiology, etiology, and classification. In: Daly AF (ed). Acromegaly and its management. Philadelphia Lippincott-Raven 1996 17-19
3. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000 85 526-529 (Pubitemid 32273628)
4. Jap TS, Ho LT. Insulin secretion and sensitivity in acromegaly. Clin Physiol Biochem 1990 8 64-69
5. Clemmons DR. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 2004 113 25-27 (Pubitemid 38541628)
6. Barrande G, Pittino-Lungo M, Coste J, Ponvert D, Bertagna X, Luton JP, Bertherat J. Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. J Clin Endocrinol Metab 2000 85 3779-3785
7. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000 52 549-555 (Pubitemid 30337079)
8. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M. On behalf of the REA participants: Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry. Eur J Endocrinol 2004 151 439-446 (Pubitemid 39430260)
9. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005 90 5684-5691 (Pubitemid 41415476)
10. Jørgensen JOL, Feldt-Rasmussen U, Frystyk J, Chen J-W, Kristensen LO, Hagen C, ørskovH. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005 90 5627-5631
11. Ronchi CL, Varca V, Beck-Peccoz P, Orsi E, Donadio F, Baccarelli A, Giavoli C, Ferrante E, Lania A, Spada A, Arosio M. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 2006 91 121-128 (Pubitemid 43069127)
12. Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 2008 93 2639-2646 (Pubitemid 352008531)
13. Brazeau P, Vale W, Burnus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973 179 77-79
14. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996 334 246-254 (Pubitemid 26030676)
15. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2003 2 999-1017 (Pubitemid 37540581)
16. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005 90 4465-4473 (Pubitemid 41159328)
17. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006 91 2112-2118 (Pubitemid 43854991)
18. Ronchi C, Epaminonda P, Cappiello V, Beck-Peccoz P, Arosio M. Effects of two different somatostatin analogs on glucose tolerance in acromegaly. J Endocrinol Invest 2002 25 502-507 (Pubitemid 34661837)
19. Parkinson C, Drake WM, Roberts ME, Meeran K, Besser GM, Trainer PJ. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. J Clin Endocrinol Metab 2002 87 1797-1804 (Pubitemid 34615271)
20. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clin Endocrinol (Oxf) 2003 59 492-499 (Pubitemid 37188181)
21. Ben-Shlomo A, Melmed S. Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 2008 286 192-198
22. Giustina A, Girelli A, Buffoli MG, Cimino A, Legati F, Valentini U, Giustina G. Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin. Diabetes Res Clin Pract 1991 14 47-54
23. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009 94 1500-1508
24. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic glucose clamp. Diabetes Care 1999 22 1462-1470 (Pubitemid 29418240)
25. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419 (Pubitemid 15018832)
26. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004 25 102-152 (Pubitemid 38269977)
27. Colao A, Auriemma RS, Savastano S, Galdiero M, Grasso LF, Lombardi G, Pivonello R. Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab 2009 94 2907-2914
28. Carmichael JD, Bonert VS, Mirocha JM, Melmed S. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 2009 94 523-527
29. Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Haeften T, Renn W, Gerich J. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000 23 295-301 (Pubitemid 30131733)